Sequencing Panels. Oncology Genetics Study

At Bioarray we provide an oncology genetics study with the objective of detecting alterations associated to the presence or sensitivity towards certain types of cancer.

In order to do so, we use two of the most demanded technologies in the field of oncological diagnosis: microarray and next-generation sequencing. These two technologies guarantee an optimal reliability in the results, by means of a complete bioinformatic analysis.

Servicios de oncología general

Our professional team uses CytoChip designs by Illumina that include 20,000 probes aimed at detecting up to 670 gene alterations of cancer. To be specific, we use the formats 4x180K and 4x180K SNP to cover the different possibilities of the diagnosis.

With such technology, Bioarray offers an oncology analysis able to diagnose a genetic anomaly that entails the duplication, loss or translocation of certain genes, with only one assay and in high resolution.

Next-generation sequencing oncology services

In next-generation sequencing we offer different panels by means of NGS:

• Family breast cancer. A genetic diagnosis system is based on NGS that leads to sequencing and identifying mutations in genes BRCA1 and BRCA 2 associated with breast cancer. The objective is to detect the disease early and select the most effective treatment for the patient.
• Hereditary nonpolyposis colorectal cancer (HNPCC). A genetic analysis based on sequencing and identifying the mutations that are present in genes MLH1, MSH2 and MSH6 in only one assay.
• Colon or lung cancer. A genetic diagnosis system based on NGS that leads to sequencing and identifying mutations in 22 genes associated to the disease in only one assay, reducing the cost and time for the patient and clinical staff.
• Cancer Hotspot V2. This is one of our most complete panels to detect genomic regions known as ‘hotspots’, as a consequence of its high mutation rate in humans. In total, it means that there is a simultaneous sequencing of 50 oncogenes and tumor suppressor genes. Its extremely uniform coverage means there is a considerable amount saved, as well as improving the reliability of the result.
• Complete cancer panel. This is an ideal tool to carry out a complete study of the regions associated to oncogenes and exons of tumor suppressor genes. It includes the sequencing of 396 genes and a subsequent bioinformatic analysis.